Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Substitution, Crossover, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pf 06650833 Delivered in Multiple Formulations in Healthy Subjects Under Fasted and Fed Conditions

Next Previous
Trial Profile

A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Substitution, Crossover, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pf 06650833 Delivered in Multiple Formulations in Healthy Subjects Under Fasted and Fed Conditions

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zimlovisertib (Primary) ; Zimlovisertib (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Pfizer

Most Recent Events

  • 08 Nov 2017 Results from the single and multiple ascending dose (SAD, MAD) studies of PF-06650833 in healthy subjects assessing safety and efficacy, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
  • 01 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 11 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top